Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy
暂无分享,去创建一个
H. Tawbi | R. Ferris | N. Rizvi | M. Hellmann | H. Kluger | R. Mehra | F. Ademuyiwa | S. Goldberg | I. Rhee | Z. Cao | R. Sullivan | Helen X. Chen | Helen X Chen | J. C. Park
[1] N. Girard,et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. , 2022, The New England journal of medicine.
[2] Benjamin Wolfson,et al. From Immunogenic Cell Death to Immunogenic Modulation: Select Chemotherapy Regimens Induce a Spectrum of Immune-Enhancing Activities in the Tumor Microenvironment , 2021, Frontiers in Oncology.
[3] T. Powles,et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma , 2021, Nature.
[4] Lisa M. Ebert,et al. Effects of Chemotherapy Agents on Circulating Leukocyte Populations: Potential Implications for the Success of CAR-T Cell Therapies , 2021, Cancers.
[5] Michal Sheffer,et al. Considerations for treatment duration in responders to immune checkpoint inhibitors , 2021, Journal for ImmunoTherapy of Cancer.
[6] R. Sullivan,et al. Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort , 2021, Journal for ImmunoTherapy of Cancer.
[7] S. Friesland,et al. Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors. , 2021, European journal of cancer.
[8] P. Ascierto,et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC) , 2019, Nature Medicine.
[9] S. Molina-Pinelo,et al. Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy , 2020, Cancers.
[10] O. Molinier,et al. Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab , 2020, Journal of clinical medicine.
[11] S. Grupp,et al. Lingering effects of chemotherapy on mature T cells impair proliferation. , 2020, Blood advances.
[12] C. Robert,et al. Immunotherapy discontinuation — how, and when? Data from melanoma as a paradigm , 2020, Nature Reviews Clinical Oncology.
[13] M. Verma,et al. Role of membrane-embedded drug efflux ABC transporters in the cancer chemotherapy , 2020, Oncology reviews.
[14] Correction: Consensus guidelines for the definition, detection and interpretation of immunogenic cell death , 2020, Journal for immunotherapy of cancer.
[15] M. Hellmann,et al. Acquired Resistance to Immune Checkpoint Inhibitors. , 2020, Cancer cell.
[16] Vanessa M. Hubbard-Lucey,et al. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce , 2020, Journal for ImmunoTherapy of Cancer.
[17] A. Gao,et al. Resistance Mechanisms to Taxanes and PARP Inhibitors in Advanced Prostate Cancer. , 2020, Current opinion in endocrine and metabolic research.
[18] J. Taube,et al. Neoadjuvant checkpoint blockade for cancer immunotherapy , 2020, Science.
[19] S. Shah,et al. Pembrolizumab + chemotherapy for advanced G/GEJ adenocarcinoma (GC): The phase III KEYNOTE-062 study , 2019, Annals of Oncology.
[20] A. Ribas,et al. Tumour-intrinsic resistance to immune checkpoint blockade , 2019, Nature Reviews Immunology.
[21] R. Bell,et al. Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance , 2019, Journal of Immunotherapy for Cancer.
[22] M. Smyth,et al. Cancer immunoediting and resistance to T cell-based immunotherapy , 2018, Nature Reviews Clinical Oncology.
[23] E. Winer,et al. Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer , 2018, The New England journal of medicine.
[24] W. J. Valente,et al. Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA , 2018, Nature Communications.
[25] Deric M. Park,et al. Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy , 2018, Journal of Immunotherapy for Cancer.
[26] Qiaohong Wang,et al. Pseudoprogression and hyperprogression after checkpoint blockade , 2018, International immunopharmacology.
[27] A. Shaw,et al. Tumour heterogeneity and resistance to cancer therapies , 2018, Nature Reviews Clinical Oncology.
[28] Peter K. Sorger,et al. Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy , 2017, Cell.
[29] Jing Zhao,et al. Harness the synergy between targeted therapy and immunotherapy: what have we learned and where are we headed? , 2017, Oncotarget.
[30] Behzad Baradaran,et al. The Different Mechanisms of Cancer Drug Resistance: A Brief Review , 2017, Advanced pharmaceutical bulletin.
[31] J. Wargo,et al. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy , 2017, Cell.
[32] Arun Ahuja,et al. Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer , 2016, bioRxiv.
[33] Yu Sun. Tumor microenvironment and cancer therapy resistance. , 2016, Cancer letters.
[34] Erich P Huang,et al. RECIST 1.1-Update and clarification: From the RECIST committee. , 2016, European journal of cancer.
[35] J. Wargo,et al. Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy , 2016, Current Oncology Reports.
[36] Shohei Koyama,et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints , 2016, Nature Communications.
[37] K. Horgan,et al. Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer , 2016, Breast Cancer Research.
[38] R. Sullivan,et al. Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy. , 2015, Seminars in oncology.
[39] L. Zitvogel,et al. Molecular mechanisms of ATP secretion during immunogenic cell death , 2013, Cell Death and Differentiation.
[40] I. Mellman,et al. Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.
[41] L. Zitvogel,et al. Immunological aspects of cancer chemotherapy , 2008, Nature Reviews Immunology.
[42] Laurence Zitvogel,et al. Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.
[43] C. Mackall,et al. Constraints on CD4 recovery postchemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells. , 1997, Blood.
[44] N. Nissen,et al. Anthracycline resistance. , 1989, Acta oncologica.